Tirzepatide Leads All Diabetes Drugs in Blood Sugar and Weight Loss — Network Meta-Analysis of 28 Trials
Tirzepatide 15 mg produced the largest HbA1c reduction (-2.24%) and weight loss (-8.74 kg) among seven diabetes medications compared in a network meta-analysis of 28 RCTs with 8,499 patients.
Quick Facts
What This Study Found
Tirzepatide 15 mg reduced HbA1c by 2.24% and weight by 8.74 kg vs placebo — the most effective of all seven medications. Liraglutide outperformed SGLT2i for glycemia; SGLT2i excelled in blood pressure.
Key Numbers
Compared: tirzepatide, liraglutide, canagliflozin, ertugliflozin, empagliflozin, dapagliflozin, and henagliflozin. Searched through February 2024.
How They Did This
Bayesian network meta-analysis of 28 randomized controlled trials (8,499 participants) comparing tirzepatide (5/10/15 mg), liraglutide (1.2/1.8 mg), and five SGLT2 inhibitors for HbA1c, weight, blood pressure, and safety outcomes.
Why This Research Matters
This is one of the first comprehensive network comparisons of tirzepatide against both GLP-1 agonists and SGLT2 inhibitors, helping clinicians choose the right medication based on each patient's primary treatment goals.
The Bigger Picture
As the type 2 diabetes treatment landscape rapidly evolves with novel peptide-based therapies, head-to-head comparisons help clinicians navigate the expanding options and match medications to individual patient needs — prioritizing weight loss, glycemic control, or cardiovascular protection.
What This Study Doesn't Tell Us
Network meta-analysis relies on indirect comparisons; trial populations differed; only studied as monotherapy add-ons (not combinations); short-term outcomes may not capture long-term cardiovascular benefits; SGLT2i cardiac and renal protection not captured by these endpoints.
Questions This Raises
- ?How would tirzepatide compare to semaglutide directly in this framework?
- ?Do SGLT2 inhibitors' unique renal and heart failure benefits offset their lower glycemic efficacy?
- ?What is the optimal combination strategy when single agents aren't sufficient?
Trust & Context
- Key Stat:
- −8.74 kg weight loss with tirzepatide 15 mg vs placebo — the most among all 7 drugs compared
- Evidence Grade:
- Moderate evidence from a well-conducted network meta-analysis of 28 RCTs, limited by indirect comparisons and heterogeneity between trial populations.
- Study Age:
- Published in 2024 with literature through February 2024, providing a current comparison of the latest diabetes medication options.
- Original Title:
- Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis.
- Published In:
- BMC endocrine disorders, 24(1), 278 (2024)
- Authors:
- Teng, Yunjie, Fan, Xue, Yu, Rui(3), Yang, Xiaoping
- Database ID:
- RPEP-09376
Evidence Hierarchy
Combines results from multiple studies to find an overall pattern.
What do these levels mean? →Frequently Asked Questions
Which diabetes medication works best for both blood sugar and weight loss?
Tirzepatide at the highest dose (15 mg) was the clear winner, reducing HbA1c by 2.24% and weight by 8.74 kg — significantly more than any other medication studied, including liraglutide and five different SGLT2 inhibitors.
Are SGLT2 inhibitors still worth taking compared to tirzepatide?
Yes — while tirzepatide is superior for blood sugar and weight, SGLT2 inhibitors (especially canagliflozin) were best for blood pressure reduction. They also have proven kidney and heart failure protection benefits not captured in this analysis.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09376APA
Teng, Yunjie; Fan, Xue; Yu, Rui; Yang, Xiaoping. (2024). Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis.. BMC endocrine disorders, 24(1), 278. https://doi.org/10.1186/s12902-024-01805-z
MLA
Teng, Yunjie, et al. "Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis.." BMC endocrine disorders, 2024. https://doi.org/10.1186/s12902-024-01805-z
RethinkPeptides
RethinkPeptides Research Database. "Evaluation and comparison of efficacy and safety of tirzepat..." RPEP-09376. Retrieved from https://rethinkpeptides.com/research/teng-2024-evaluation-and-comparison-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.